Browse News
Filter News
Found 91 articles
-
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
5/9/2022
Brii Biosciences Limited today announced new data demonstrating that its long-acting COVID-19 neutralizing antibody therapy, the amubarvimab/romlusevimab combination, retains neutralizing activity against the Omicron BA.2 SARS-CoV-2 subvariant.
-
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/5/2022
Vir Biotechnology, Inc. provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
-
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
4/27/2022
Vir Biotechnology, Inc. announced that the Company will review its robust hepatitis portfolio, including initial data from the first cohort of the MARCH trial evaluating VIR-2218 in combination with VIR-3434, as well as a new program aimed at chronic hepatitis D. Details will be discussed at 12:00 pm ET / 9:00 am PT during Vir’s virtual Hepatitis Portfolio R&D Day.
-
Qpex Biopharma Announces Presentation of Clinical Data for Ultra-Broad Spectrum β-lactamase Inhibitor Xeruborbactam and the Lipopeptide QPX9003 at ECCMID 2022 Meeting
4/21/2022
Qpex Biopharma, Inc. today announced the company will present new clinical data for their β-lactamase inhibitor xeruborbactam (formerly QPX7728) and synthetic lipopeptide QPX9003 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held on April 23-26, 2022.
-
BioSpace Movers & Shakers, April 8
4/8/2022
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week. -
Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development
4/6/2022
Abata Therapeutics today announced the formation of the Abata Advisory Board, chaired by Diane Mathis, Ph.D., co-founder of Abata.
-
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
3/31/2022
Brii Biosciences Limited presented new data from a Phase 2 randomized, double-blind, placebo-controlled trial of BRII-835 in Chinese patients with chronic hepatitis B virus infection, at the 31st Conference of Asian Pacific Association for the Study of the Liver 2022, taking place virtually from March 30 to April 3 in Seoul, South Korea.
-
Qpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens
3/30/2022
Qpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens.
-
Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
3/29/2022
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that TSB Therapeutics (Beijing) Co., Ltd. ("TSB Therapeutics"), a joint venture majority-owned by the Company, is partnering with Sinopharm Holding Co., Ltd.
-
Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform
3/29/2022
Artizan Biosciences, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,299,790 that broadens the use of the company’s proprietary IgA-SEQ™ discovery platform.
-
Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
3/22/2022
Brii Biosciences Limited ("Brii Bio", "we" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced a corporate update and reported financial results for the full year ended December 31, 2021.
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer
2/23/2022
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as Chief Business Officer.
-
Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.
-
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
-
BioSpace Movers & Shakers, Jan. 28
1/28/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
1/27/2022
Brii Biosciences Limited today announced the appointment of Karen D. Neuendorff as Chief People Officer and Head of Human Resources (HR).
-
Qpex Biopharma Announces Progress on Three Clinical Stage Programs for Antibiotic-Resistant Pathogens and Corporate Update
1/19/2022
Jan. 19, 2022 13:00 UTC Oral and IV products based on xeruborbactam (formerly known as QPX7728), and QPX9003 are advancing in clinical studies All three products have received Qualified Infectious Disease Product Designation (QIDP) from the U.S. Food and Drug Administration (FDA) for multiple potential indications The Biomedical Advanced Research and Development Authority (BARDA) exercised a $15M option in 2021 to support continued clinical advancement of pipe
-
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
1/18/2022
Artizan Biosciences, Inc. today announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (“IBD”).
-
VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio
1/5/2022
VBI Vaccines Inc. today announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 (BRII-179), an immunotherapeutic candidate targeting chronic hepatitis B virus (HBV).